Moberg Pharma AB (publ) (MOB) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning all, good afternoon all, and welcome to the Movericks Family Conference call. My name is Adam and I'll be your operator today. If you'd like to ask a question in the Q&A portion of today's call, please press star followed by 1 on your telephone keypad. I'll now hand the call to Anna Young to begin. So Anna, please go ahead when you are ready. Thank you, and welcome everyone to this telephone conference following the press release yesterday evening. Please note that this call will be recorded and will be made available on our webpage. With me today are our Chief Medical Officer Anders Bergessinger and our Chief Scientific Officer Amir Tavakol. Today, we will provide an important update on our ongoing efforts related to our product MOB15. We understand that there is a significant interest in the progress of this program, and we aim to be as clear, transparent, and forthcoming as possible. Our objective is to address not only the applying results from our North American Play Treats study, but also preliminary statistics strategic implications that arise from the data. However, I want to emphasize that this is top-line data that we have just received, and both we and our partners need time to thoroughly analyze and digest the information before making conclusions. I will begin with an overview of the study, key results, and our reflections on what these results mean for our business strategy going forward. After that, we will open up the floor for questions. So, turning to that overview of the study, The North American study was conducted at 33 study centers across the U.S. and Canada, including a total of 384 patients. Two starts of the patients received MOB15, while the remaining starts received a vehicle. To maintain consistency, we deliberately kept key ...